{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:28:58Z","timestamp":1765232938832,"version":"3.37.3"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1HL138481","HL098216","DK098331"],"award-info":[{"award-number":["RO1HL138481","HL098216","DK098331"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LAM Research Foundation","award":["0124B07-17"],"award-info":[{"award-number":["0124B07-17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Tuberous sclerosis complex (TSC) is a genetic disorder that cause tumors to form in many organs. These lesions may lead to epilepsy, autism, developmental delay, renal, and pulmonary failure. Loss of function mutations in <jats:italic>TSC1<\/jats:italic> and <jats:italic>TSC2<\/jats:italic> genes by aberrant activation of the mechanistic target of rapamycin (mTORC1) signaling pathway are the known causes of TSC. Therefore, targeting mTORC1 becomes a most available therapeutic strategy for TSC. Although mTORC1 inhibitor rapamycin and Rapalogs have demonstrated exciting results in the recent clinical trials, however, tumors rebound and upon the discontinuation of the mTORC1 inhibition. Thus, understanding the underlying molecular mechanisms responsible for rapamycin-induced cell survival becomes an urgent need. Identification of additional molecular targets and development more effective remission-inducing therapeutic strategies are necessary for TSC patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We have discovered an Mitogen-activated protein kinase (MAPK)-evoked positive feedback loop that dampens the efficacy of mTORC1 inhibition. Mechanistically, mTORC1 inhibition increased MEK1-dependent activation of MAPK in TSC-deficient cells. Pharmacological inhibition of MAPK abrogated this feedback loop activation. Importantly, the combinatorial inhibition of mTORC1 and MAPK induces the death of TSC2-deficient cells.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our results provide a rationale for dual targeting of mTORC1 and MAPK pathways in TSC and other mTORC1 hyperactive neoplasm.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01490-w","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T12:47:55Z","timestamp":1598878075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex"],"prefix":"10.1186","volume":"15","author":[{"given":"Yiyang","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane J.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"issue":"13","key":"1490_CR1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"19","key":"1490_CR2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801\u201311.","journal-title":"N Engl J Med"},{"issue":"4","key":"1490_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","volume":"47","author":"CC Dibble","year":"2012","unstructured":"Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell. 2012;47(4):535\u201346.","journal-title":"Mol Cell"},{"issue":"1","key":"1490_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1097-2765(02)00568-3","volume":"10","author":"BD Manning","year":"2002","unstructured":"Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase\/akt pathway. Mol Cell. 2002;10(1):151\u201362.","journal-title":"Mol Cell"},{"issue":"16","key":"1490_CR5","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926\u201345.","journal-title":"Genes Dev"},{"issue":"1","key":"1490_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12(1):21\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"1490_CR7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell."},{"issue":"3","key":"1490_CR8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014;19(3):373\u20139.","journal-title":"Cell Metab"},{"issue":"2","key":"1490_CR9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"17","key":"1490_CR10","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595\u2013606.","journal-title":"N Engl J Med"},{"issue":"6","key":"1490_CR11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","volume":"22","author":"A Britschgi","year":"2012","unstructured":"Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U, et al. JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012;22(6):796\u2013811.","journal-title":"Cancer Cell"},{"issue":"8","key":"1490_CR12","doi-asserted-by":"crossref","first-page":"djv123","DOI":"10.1093\/jnci\/djv123","volume":"107","author":"RA Francois","year":"2015","unstructured":"Francois RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M. Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors. J Natl Cancer Inst. 2015;107(8):djv123.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1490_CR13","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1073\/pnas.1216013110","volume":"110","author":"C Posch","year":"2013","unstructured":"Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, et al. Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013;110(10):4015\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1490_CR14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10549-011-1420-7","volume":"131","author":"H Zhao","year":"2012","unstructured":"Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, et al. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat. 2012;131(2):425\u201336.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1490_CR15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1165\/rcmb.2009-0050OC","volume":"42","author":"PS Lee","year":"2010","unstructured":"Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, et al. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol. 2010;42(2):227\u201334.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"1490_CR16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K Duvel","year":"2010","unstructured":"Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39(2):171\u201383.","journal-title":"Mol Cell"},{"issue":"7170","key":"1490_CR17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","volume":"450","author":"JT Cunningham","year":"2007","unstructured":"Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450(7170):736\u201340.","journal-title":"Nature."},{"issue":"16","key":"1490_CR18","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1038\/emboj.2011.257","volume":"30","author":"S Pena-Llopis","year":"2011","unstructured":"Pena-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, Wolff NC, Tran TA, Zou L, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J. 2011;30(16):3242\u201358.","journal-title":"EMBO J"},{"issue":"2","key":"1490_CR19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","volume":"21","author":"T Muranen","year":"2012","unstructured":"Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, et al. Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell. 2012;21(2):227\u201339.","journal-title":"Cancer Cell"},{"key":"1490_CR20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1476-4598-8-75","volume":"8","author":"A Akcakanat","year":"2009","unstructured":"Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer. 2009;8:75.","journal-title":"Mol Cancer"},{"issue":"1","key":"1490_CR21","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","volume":"5","author":"TF Cloughesy","year":"2008","unstructured":"Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5(1):e8.","journal-title":"PLoS Med"},{"issue":"139","key":"1490_CR22","doi-asserted-by":"crossref","first-page":"139ra84","DOI":"10.1126\/scitranslmed.3003923","volume":"4","author":"HE Thomas","year":"2012","unstructured":"Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med. 2012;4(139):139ra84.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1490_CR23","doi-asserted-by":"crossref","first-page":"e7373","DOI":"10.1371\/journal.pone.0007373","volume":"4","author":"RH Jimenez","year":"2009","unstructured":"Jimenez RH, Boylan JM, Lee JS, Francesconi M, Castellani G, Sanders JA, et al. Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines. PLoS One. 2009;4(10):e7373.","journal-title":"PLoS One"},{"issue":"6","key":"1490_CR24","first-page":"1568","volume":"146","author":"SR Howe","year":"1995","unstructured":"Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol. 1995;146(6):1568\u201379.","journal-title":"Am J Pathol"},{"issue":"11","key":"1490_CR25","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1210\/endo.136.11.7588234","volume":"136","author":"SR Howe","year":"1995","unstructured":"Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology. 1995;136(11):4996\u20135003.","journal-title":"Endocrinology."},{"issue":"8","key":"1490_CR26","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1073\/pnas.0810790106","volume":"106","author":"JJ Yu","year":"2009","unstructured":"Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009;106(8):2635\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1490_CR27","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1128\/MCB.00289-08","volume":"28","author":"J Huang","year":"2008","unstructured":"Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28(12):4104\u201315.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"1490_CR28","doi-asserted-by":"crossref","first-page":"L694","DOI":"10.1152\/ajplung.00204.2003","volume":"286","author":"J Yu","year":"2004","unstructured":"Yu J, Astrinidis A, Howard S, Henske EP. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L694\u2013700.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"8","key":"1490_CR29","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","volume":"112","author":"H Zhang","year":"2003","unstructured":"Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, et al. Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003;112(8):1223\u201333.","journal-title":"J Clin Invest"},{"issue":"2","key":"1490_CR30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","volume":"103","author":"T Schmelzle","year":"2000","unstructured":"Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103(2):253\u201362.","journal-title":"Cell."},{"issue":"8","key":"1490_CR31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/156800908786733513","volume":"8","author":"P Baldo","year":"2008","unstructured":"Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):647\u201365.","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"1490_CR32","doi-asserted-by":"crossref","first-page":"e63578","DOI":"10.1371\/journal.pone.0063578","volume":"8","author":"A Li","year":"2013","unstructured":"Li A, Hardy R, Stoner S, Tuckermann J, Seibel M, Zhou H. Deletion of mesenchymal glucocorticoid receptor attenuates embryonic lung development and abdominal wall closure. PLoS One. 2013;8(5):e63578.","journal-title":"PLoS One"},{"issue":"4","key":"1490_CR33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00432-014-1803-3","volume":"141","author":"HJ Lim","year":"2015","unstructured":"Lim HJ, Crowe P, Yang JL. Current clinical regulation of PI3K\/PTEN\/Akt\/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol. 2015;141(4):671\u201389.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1490_CR34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011;6(1):17\u201327.","journal-title":"Target Oncol"},{"issue":"9861","key":"1490_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332.","journal-title":"Lancet."},{"issue":"9869","key":"1490_CR36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet."},{"key":"1490_CR37","unstructured":"Summary of the risk management plan for Afinitor and Votubia (everolimus). European Medicines Agency. 2011:Online."},{"issue":"4","key":"1490_CR38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/157015912804499537","volume":"10","author":"P Curatolo","year":"2012","unstructured":"Curatolo P, Moavero R. mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol. 2012;10(4):404\u201315.","journal-title":"Curr Neuropharmacol"},{"key":"1490_CR39","doi-asserted-by":"crossref","unstructured":"Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000Res. 2016;5:F1000 Faculty Rev-2078.","DOI":"10.12688\/f1000research.9207.1"},{"issue":"2","key":"1490_CR40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","volume":"10","author":"TL Phung","year":"2006","unstructured":"Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10(2):159\u201370.","journal-title":"Cancer Cell"},{"issue":"2","key":"1490_CR41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell. 2006;22(2):159\u201368.","journal-title":"Mol Cell"},{"key":"1490_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-3-319-91442-8_8","volume":"211","author":"J Hasskarl","year":"2018","unstructured":"Hasskarl J. Everolimus. Recent Results Cancer Res. 2018;211:101\u201323.","journal-title":"Recent Results Cancer Res"},{"key":"1490_CR43","doi-asserted-by":"crossref","unstructured":"Granata S, Dalla Gassa A, Carraro A, Brunelli M, Stallone G, Lupo A, et al. Sirolimus and everolimus pathway: reviewing candidate genes influencing their intracellular effects. Int J Mol Sci. 2016;17(5):735.","DOI":"10.3390\/ijms17050735"},{"issue":"12","key":"1490_CR44","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","volume":"17","author":"JP MacKeigan","year":"2015","unstructured":"MacKeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro-Oncology. 2015;17(12):1550\u20139.","journal-title":"Neuro-Oncology"},{"key":"1490_CR45","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske EP, J\u00f3\u017awiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035.","journal-title":"Nat Rev Dis Primers"},{"key":"1490_CR46","doi-asserted-by":"crossref","first-page":"9820181","DOI":"10.1155\/2017\/9820181","volume":"2017","author":"F Palavra","year":"2017","unstructured":"Palavra F, Robalo C, Reis F. Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex. Oxidative Med Cell Longev. 2017;2017:9820181.","journal-title":"Oxidative Med Cell Longev"},{"issue":"10","key":"1490_CR47","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","volume":"57","author":"EJ Hess","year":"2016","unstructured":"Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617\u201324.","journal-title":"Epilepsia."},{"issue":"3","key":"1490_CR48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270\u20138.","journal-title":"Lancet Neurol"},{"key":"1490_CR49","doi-asserted-by":"crossref","unstructured":"Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014(3):CD009270.","DOI":"10.1002\/14651858.CD009270.pub3"},{"issue":"3","key":"1490_CR50","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.eplepsyres.2012.10.010","volume":"104","author":"M Jennesson","year":"2013","unstructured":"Jennesson M, van Eeghen AM, Caruso PA, Paolini JL, Thiele EA. Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. Epilepsy Res. 2013;104(3):269\u201374.","journal-title":"Epilepsy Res"},{"issue":"10","key":"1490_CR51","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1528-1167.2005.00266.x","volume":"46","author":"EH Kossoff","year":"2005","unstructured":"Kossoff EH, Thiele EA, Pfeifer HH, McGrogan JR, Freeman JM. Tuberous sclerosis complex and the ketogenic diet. Epilepsia. 2005;46(10):1684\u20136.","journal-title":"Epilepsia."},{"issue":"23","key":"1490_CR52","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","volume":"87","author":"DA Krueger","year":"2016","unstructured":"Krueger DA, Wilfong AA, Mays M, Talley CM, Agricola K, Tudor C, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology. 2016;87(23):2408\u201315.","journal-title":"Neurology."},{"issue":"2","key":"1490_CR53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5698\/1535-7511.17.2.91","volume":"17","author":"K Nickels","year":"2017","unstructured":"Nickels K. Cannabidiol in patients with intractable epilepsy due to TSC: a possible medication but not a miracle. Epilepsy Curr. 2017;17(2):91\u20132.","journal-title":"Epilepsy Curr"},{"issue":"17","key":"1490_CR54","first-page":"5173","volume":"63","author":"N El-Hashemite","year":"2003","unstructured":"El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 2003;63(17):5173\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"1490_CR55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1172\/JCI40221","volume":"120","author":"M Karbowniczek","year":"2010","unstructured":"Karbowniczek M, Zitserman D, Khabibullin D, Hartman T, Yu J, Morrison T, et al. The evolutionarily conserved TSC\/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest. 2010;120(1):93\u2013102.","journal-title":"J Clin Invest"},{"issue":"20","key":"1490_CR56","first-page":"5645","volume":"62","author":"HL Kenerson","year":"2002","unstructured":"Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 2002;62(20):5645\u201350.","journal-title":"Cancer Res"},{"issue":"3","key":"1490_CR57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/gcc.20118","volume":"42","author":"L Lee","year":"2005","unstructured":"Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosom Cancer. 2005;42(3):213\u201327.","journal-title":"Genes Chromosom Cancer"},{"issue":"30","key":"1490_CR58","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1073\/pnas.1104361108","volume":"108","author":"A Parkhitko","year":"2011","unstructured":"Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M, et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62\/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci U S A. 2011;108(30):12455\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1490_CR59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/lrb.2009.0013","volume":"8","author":"DJ Kwiatkowski","year":"2010","unstructured":"Kwiatkowski DJ. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lymphat Res Biol. 2010;8(1):51\u20137.","journal-title":"Lymphat Res Biol"},{"issue":"1","key":"1490_CR60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/lrb.2009.0020","volume":"8","author":"J Yu","year":"2010","unstructured":"Yu J, Henske EP. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the \u201cperfect storm\u201d of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol. 2010;8(1):43\u20139.","journal-title":"Lymphat Res Biol"},{"issue":"1","key":"1490_CR61","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1038\/s41598-019-39418-5","volume":"9","author":"M Valianou","year":"2019","unstructured":"Valianou M, Filippidou N, Johnson DL, Vogel P, Zhang EY, Liu X, et al. Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells. Sci Rep. 2019;9(1):3015.","journal-title":"Sci Rep"},{"issue":"5","key":"1490_CR62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trecan.2016.03.008","volume":"2","author":"E Ilagan","year":"2016","unstructured":"Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer. 2016;2(5):241\u201351.","journal-title":"Trends Cancer"},{"key":"1490_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2016.03.015","volume":"60","author":"M Sahin","year":"2016","unstructured":"Sahin M, Henske EP, Manning BD, Ess KC, Bissler JJ, Klann E, et al. Advances and future directions for tuberous sclerosis complex research: recommendations from the 2015 strategic planning conference. Pediatr Neurol. 2016;60:1\u201312.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"1490_CR64","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","volume":"22","author":"A Efeyan","year":"2010","unstructured":"Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22(2):169\u201376.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"1490_CR65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1541-7786.MCR-13-0258-T","volume":"12","author":"AA Parkhitko","year":"2013","unstructured":"Parkhitko AA, Priolo C, Coloff JL, Yun J, Wu JJ, Mizumura K, et al. Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-Aminonicotinamide. Mol Cancer Res. 2013;12(1):48\u201357.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"1490_CR66","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1172\/JCI86120","volume":"126","author":"J Xu","year":"2016","unstructured":"Xu J, Pham CG, Albanese SK, Dong Y, Oyama T, Lee CH, et al. Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. J Clin Invest. 2016;126(9):3526\u201340.","journal-title":"J Clin Invest"},{"issue":"9","key":"1490_CR67","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065\u201374.","journal-title":"J Clin Invest"},{"issue":"16","key":"1490_CR68","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/0008-5472.CAN-15-2629","volume":"76","author":"J Li","year":"2016","unstructured":"Li J, Shin S, Sun Y, Yoon SO, Li C, Zhang E, et al. mTORC1-driven tumor cells are highly sensitive to therapeutic targeting by antagonists of oxidative stress. Cancer Res. 2016;76(16):4816\u201327.","journal-title":"Cancer Res"},{"issue":"1","key":"1490_CR69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1541-7786.MCR-14-0440","volume":"13","author":"D Medvetz","year":"2015","unstructured":"Medvetz D, Sun Y, Li C, Khabibullin D, Balan M, Parkhitko A, et al. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting. Mol Cancer Res. 2015;13(1):50\u201362.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"1490_CR70","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cellsig.2007.01.006","volume":"19","author":"C Santiskulvong","year":"2007","unstructured":"Santiskulvong C, Rozengurt E. Protein kinase Calpha mediates feedback inhibition of EGF receptor transactivation induced by Gq-coupled receptor agonists. Cell Signal. 2007;19(6):1348\u201357.","journal-title":"Cell Signal"},{"issue":"14","key":"1490_CR71","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/emboj.2008.120","volume":"27","author":"V Facchinetti","year":"2008","unstructured":"Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008;27(14):1932\u201343.","journal-title":"EMBO J"},{"issue":"14","key":"1490_CR72","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/emboj.2008.119","volume":"27","author":"T Ikenoue","year":"2008","unstructured":"Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008;27(14):1919\u201331.","journal-title":"EMBO J"},{"issue":"3","key":"1490_CR73","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jcp.21246","volume":"213","author":"E Rozengurt","year":"2007","unstructured":"Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007;213(3):589\u2013602.","journal-title":"J Cell Physiol"},{"issue":"6","key":"1490_CR74","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.molcel.2008.04.027","volume":"30","author":"F Hong","year":"2008","unstructured":"Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008;30(6):701\u201311.","journal-title":"Mol Cell"},{"issue":"55","key":"1490_CR75","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/sj.onc.1205962","volume":"21","author":"A Astrinidis","year":"2002","unstructured":"Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene. 2002;21(55):8470\u20136.","journal-title":"Oncogene."},{"issue":"1","key":"1490_CR76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20131080","volume":"211","author":"C Li","year":"2014","unstructured":"Li C, Lee PS, Sun Y, Gu X, Zhang E, Guo Y, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med. 2014;211(1):15\u201328.","journal-title":"J Exp Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01490-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:22:29Z","timestamp":1629159749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01490-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01490-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"1 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Cincinnati Institutional Animal Care and Use Committee approved all procedures described according to standards as outlined in The Guide for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}